117 related articles for article (PubMed ID: 23277485)
21. Molecular markers of therapeutic resistance in breast cancer.
Zhou L; Luo Y; Li K; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Jul; 44(7):1421-8. PubMed ID: 23434145
[TBL] [Abstract][Full Text] [Related]
22. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
23. Hand-foot syndrome in breast cancer patients receiving adjuvant chemotherapy.
Lee CK; Lynch J
Intern Med J; 2007 Apr; 37(4):281-2. PubMed ID: 17388876
[No Abstract] [Full Text] [Related]
24. The impact of the loco-regional treatment in elderly breast cancer patients: hypo-fractionated exclusive radiotherapy, single institution long-term results.
Chargari C; Kirova YM; Laki F; Savignoni A; Dorval T; Dendale R; Bollet MA; Fourquet A; Campana F;
Breast; 2010 Oct; 19(5):413-6. PubMed ID: 20483616
[TBL] [Abstract][Full Text] [Related]
25. Uterine metastases from breast cancer in a patient under tamoxifen therapy. Case report.
Dessole S; Cherchi PL; Ruiu GA; Meloni GB; Cossu Rocca P
Eur J Gynaecol Oncol; 1999; 20(5-6):416-7. PubMed ID: 10609509
[TBL] [Abstract][Full Text] [Related]
26. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
27. Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
Di Vita M; Zanghì A; Lanzafame S; Cavallaro A; Piccolo G; Berretta M; Grosso G; Cappellani A
Clin Ter; 2011; 162(5):451-6. PubMed ID: 22041804
[TBL] [Abstract][Full Text] [Related]
28. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
29. Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?
Giuliani J; Bonetti A
Dig Dis Sci; 2015 Aug; 60(8):2541-3. PubMed ID: 26088368
[No Abstract] [Full Text] [Related]
30. Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer.
Singh SN; Zhu Y; Chumsri S; Kesmodel S; Gilliam BL; Riedel DJ
Clin Breast Cancer; 2014 Apr; 14(2):e53-9. PubMed ID: 24418743
[No Abstract] [Full Text] [Related]
31. Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient.
Nesković-Konstantinović Z; Susnjar S; Vasović S; Borojević N; Mitrović L; Radosević-Jelić L; Radulović S
Acta Oncol; 1996; 35(4):501-3. PubMed ID: 8695173
[No Abstract] [Full Text] [Related]
32. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.
Fitzal F; Mittlboeck M; Steger G; Bartsch R; Rudas M; Dubsky P; Riedl O; Jakesz R; Gnant M
Ann Surg Oncol; 2012 Feb; 19(2):519-26. PubMed ID: 21743980
[TBL] [Abstract][Full Text] [Related]
34. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use.
Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R
J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294
[TBL] [Abstract][Full Text] [Related]
36. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Jung M; Shin HJ; Rha SY; Jeung HC; Hong S; Moon YW; Kim HS; Oh KJ; Yang WI; Roh JK; Chung HC
Ann Surg Oncol; 2010 Dec; 17(12):3259-68. PubMed ID: 20563656
[TBL] [Abstract][Full Text] [Related]
37. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
39. T1 invasive breast lobular tumor and ductal carcinoma with HER-2 positive characteristics: Is it rationale to use adjuvant trastuzumab?
Altundag K
J BUON; 2017; 22(4):1083. PubMed ID: 28952233
[No Abstract] [Full Text] [Related]
40. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
Patel BK; Hilal T; Covington M; Zhang N; Kosiorek HE; Lobbes M; Northfelt DW; Pockaj BA
Ann Surg Oncol; 2018 May; 25(5):1350-1356. PubMed ID: 29516362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
